New hepatitis b drug shows early promise in small trial

NCT ID NCT07515209

Completed Disease control Sponsor: Huahui Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental injection called HH-006 in 36 adults with untreated chronic hepatitis B. The study aimed to check the drug's safety, how the body processes it, and whether it can lower virus levels. Participants received either HH-006 or a placebo over five weeks and were monitored for 24 weeks afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HH-006 (an experimental biologic injection)
What this could lead to: If it works, this could point toward a new treatment option for chronic hepatitis B that helps control the virus.
What could go wrong: This is a very early Phase 1 trial with only 36 people, so safety and effectiveness are not yet proven. The drug may not show strong antiviral effects or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B VIRUS INFECTION

Contacts and locations

Locations

NanFang Hospital of Southern Medical University

Guangzhou, Guangdong, 510000, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510000, China
The Eighth Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.